<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Disruption Forecast: Roche ‚Äî Analyst Perspective | The 2030 Intelligence Report</title>
    <meta name="description" content="From: The 2030 Report Global Intelligence Division">
    <meta property="og:title" content="ENTITY: ROCHE HOLDING AG">
    <meta property="og:description" content="From: The 2030 Report Global Intelligence Division">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ai2030report.com/articles/companies-europe-roche-roche-investor.html">
    <meta property="og:image" content="https://ai2030report.com/og/companies-europe-roche-roche-investor.png">
    <meta property="og:image:width" content="1200">
    <meta property="og:image:height" content="630">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="ENTITY: ROCHE HOLDING AG">
    <meta name="twitter:description" content="From: The 2030 Report Global Intelligence Division">
    <meta name="twitter:image" content="https://ai2030report.com/og/companies-europe-roche-roche-investor.png">
    <link rel="canonical" href="https://ai2030report.com/articles/companies-europe-roche-roche-investor.html">
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "ENTITY: ROCHE HOLDING AG",
        "description": "From: The 2030 Report Global Intelligence Division",
        "url": "https://ai2030report.com/articles/companies-europe-roche-roche-investor.html",
        "author": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        },
        "publisher": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        }
    }
    </script>
    <link rel="icon" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect rx='20' width='100' height='100' fill='%233b82f6'/><text x='50' y='70' font-size='55' font-weight='700' text-anchor='middle' fill='white'>30</text></svg>">
    <style>
:root {
    --bg-primary: #0a0a0f;
    --bg-secondary: #111118;
    --bg-card: #16161f;
    --bg-card-hover: #1c1c28;
    --border: #2a2a3a;
    --text-primary: #e4e4ef;
    --text-secondary: #9494a8;
    --text-muted: #6b6b80;
    --accent-blue: #3b82f6;
    --accent-purple: #8b5cf6;
    --accent-amber: #f59e0b;
    --accent-green: #10b981;
    --accent-red: #ef4444;
    --accent-cyan: #06b6d4;
    --gradient-1: linear-gradient(135deg, #3b82f6 0%, #8b5cf6 100%);
}

* {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
}

html {
    scroll-behavior: smooth;
}

body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
    background-color: var(--bg-primary);
    color: var(--text-primary);
    line-height: 1.6;
    letter-spacing: -0.3px;
}

a {
    color: var(--accent-blue);
    text-decoration: none;
    transition: color 0.2s ease;
}

a:hover {
    color: var(--accent-purple);
}

button {
    background: none;
    border: none;
    cursor: pointer;
    font-family: inherit;
}

/* Header */
.site-header {
    position: sticky;
    top: 0;
    z-index: 1000;
    background: rgba(10, 10, 15, 0.95);
    backdrop-filter: blur(10px);
    border-bottom: 1px solid var(--border);
}

.header-inner {
    max-width: 1400px;
    margin: 0 auto;
    padding: 1rem 2rem;
    display: flex;
    align-items: center;
    justify-content: space-between;
}

.site-logo {
    display: flex;
    align-items: center;
    gap: 0.5rem;
    font-weight: 700;
    font-size: 1.5rem;
    color: var(--text-primary);
    text-decoration: none;
}

.logo-mark {
    width: 2rem;
    height: 2rem;
    background: var(--gradient-1);
    border-radius: 0.5rem;
    display: flex;
    align-items: center;
    justify-content: center;
    color: white;
    font-weight: 700;
    font-size: 1.2rem;
}

.logo-text {
    display: flex;
    flex-direction: column;
    gap: 0.125rem;
}

.logo-text-main {
    font-size: 1rem;
}

.logo-text-sub {
    font-size: 0.65rem;
    color: var(--text-secondary);
    letter-spacing: 0.5px;
}

.nav-links {
    display: flex;
    gap: 2rem;
    list-style: none;
}

.nav-links a {
    color: var(--text-secondary);
    font-size: 0.95rem;
    font-weight: 500;
    transition: color 0.2s ease;
}

.nav-links a:hover {
    color: var(--text-primary);
}

.nav-toggle {
    display: none;
    flex-direction: column;
    gap: 0.4rem;
    padding: 0.5rem;
}

.nav-toggle span {
    width: 1.5rem;
    height: 2px;
    background: var(--text-primary);
    transition: all 0.3s ease;
}

/* Hero Section */
.hero {
    max-width: 1400px;
    margin: 0 auto;
    padding: 4rem 2rem;
    text-align: center;
}

.hero h1 {
    font-size: 3rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.hero .tagline {
    font-size: 1.25rem;
    color: var(--text-secondary);
    margin-bottom: 2rem;
}

.hero-stats {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
    gap: 2rem;
    margin-top: 3rem;
    padding-top: 3rem;
    border-top: 1px solid var(--border);
}

.stat {
    text-align: center;
}

.stat-number {
    font-size: 2.5rem;
    font-weight: 700;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.stat-label {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-top: 0.5rem;
}

/* Search and Filter */
.search-container {
    max-width: 1400px;
    margin: 2rem auto;
    padding: 0 2rem;
}

.search-box {
    width: 100%;
    padding: 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 1rem;
    margin-bottom: 1.5rem;
}

.search-box::placeholder {
    color: var(--text-muted);
}

.filter-buttons {
    display: flex;
    gap: 1rem;
    flex-wrap: wrap;
    margin-bottom: 2rem;
}

.filter-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-secondary);
    cursor: pointer;
    font-weight: 500;
    transition: all 0.2s ease;
}

.filter-btn:hover,
.filter-btn.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Article Grid */
.article-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
    gap: 2rem;
}

.article-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
    display: flex;
    flex-direction: column;
    cursor: pointer;
}

.article-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.card-meta {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 1rem;
    flex-wrap: wrap;
    gap: 0.5rem;
}

.card-badge {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(59, 130, 246, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.5px;
}

.badge-countries {
    background: rgba(59, 130, 246, 0.15);
    color: #3b82f6;
}

.badge-companies {
    background: rgba(139, 92, 246, 0.15);
    color: #8b5cf6;
}

.badge-sectors {
    background: rgba(245, 158, 11, 0.15);
    color: #f59e0b;
}

.badge-actions {
    background: rgba(16, 185, 129, 0.15);
    color: #10b981;
}

.badge-guides {
    background: rgba(6, 182, 212, 0.15);
    color: #06b6d4;
}

.badge-data {
    background: rgba(239, 68, 68, 0.15);
    color: #ef4444;
}

.card-audience {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(148, 148, 168, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    color: var(--text-secondary);
}

.card-title {
    font-size: 1.25rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 0.75rem;
    line-height: 1.3;
    flex-grow: 1;
}

.card-excerpt {
    font-size: 0.95rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
    line-height: 1.5;
}

.card-footer {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding-top: 1rem;
    border-top: 1px solid var(--border);
    color: var(--text-muted);
    font-size: 0.9rem;
}

.read-time {
    display: flex;
    align-items: center;
    gap: 0.35rem;
}

/* Entity Cards (Browse Pages) */
.entity-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 2rem;
}

.entity-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    text-align: center;
    transition: all 0.3s ease;
}

.entity-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.entity-icon {
    font-size: 3rem;
    margin-bottom: 1rem;
}

.entity-card h3 {
    font-size: 1.5rem;
    color: var(--text-primary);
    margin-bottom: 0.5rem;
}

.entity-card p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 0.95rem;
}

.entity-card a {
    display: inline-block;
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border-radius: 0.25rem;
    font-weight: 600;
    transition: all 0.2s ease;
}

.entity-card a:hover {
    background: var(--accent-purple);
}

/* Entity Landing Page */
.entity-landing {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem;
}

.entity-hero-section {
    padding: 3rem 0 2rem 0;
    border-bottom: 1px solid var(--border);
    margin-bottom: 2rem;
}

.entity-hero-content {
    display: flex;
    align-items: center;
    gap: 2rem;
}

.entity-hero-icon {
    font-size: 4rem;
}

.entity-hero-title {
    font-size: 2.5rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.entity-hero-section p {
    color: var(--text-secondary);
    font-size: 1.1rem;
}

/* Active nav item */
.nav-links a.nav-active {
    color: var(--accent-blue);
}

/* Clickable entity card */
.entity-card {
    cursor: pointer;
}

/* Article Page */
.article-page {
    max-width: 900px;
    margin: 0 auto;
    padding: 2rem;
}

.breadcrumb {
    display: flex;
    gap: 0.5rem;
    margin-bottom: 2rem;
    font-size: 0.9rem;
    color: var(--text-secondary);
    flex-wrap: wrap;
}

.breadcrumb a {
    color: var(--accent-blue);
}

.breadcrumb a:hover {
    color: var(--accent-purple);
}

.breadcrumb span {
    margin: 0 0.5rem;
}

.article-header {
    margin-bottom: 2rem;
}

.article-meta-bar {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
    flex-wrap: wrap;
    gap: 1rem;
}

.article-category {
    display: flex;
    gap: 0.75rem;
    align-items: center;
}

.entity-name-display {
    font-size: 1.3rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 1.5rem;
    padding-bottom: 1rem;
    border-bottom: 1px solid var(--border);
}

/* Sibling Navigation */
.sibling-nav {
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
}

.sibling-nav-label {
    font-size: 0.95rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.sibling-pills {
    display: flex;
    gap: 0.75rem;
    flex-wrap: wrap;
}

.sibling-pill {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.6rem 1.2rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 2rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    transition: all 0.2s ease;
    white-space: nowrap;
    cursor: pointer;
}

.sibling-pill a {
    color: inherit;
    text-decoration: none;
}

.sibling-pill:hover {
    border-color: var(--accent-blue);
    color: var(--accent-blue);
}

.sibling-pill.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.sibling-pill.active a {
    color: white;
}

/* Share Bar */
.share-bar {
    display: flex;
    gap: 1rem;
    align-items: center;
    margin-bottom: 2rem;
    padding: 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    flex-wrap: wrap;
}

.share-bar-label {
    font-size: 0.9rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-right: 0.5rem;
}

.share-btn {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.7rem 1.2rem;
    background: var(--bg-secondary);
    border: 1px solid var(--border);
    border-radius: 0.4rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
    white-space: nowrap;
}

.share-btn:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.share-btn.copied {
    background: var(--accent-green);
    border-color: var(--accent-green);
    color: white;
}

.article-content {
    font-size: 1.05rem;
    line-height: 1.8;
    color: var(--text-primary);
}

.article-content h1 {
    font-size: 2.5rem;
    margin-bottom: 1.5rem;
    line-height: 1.2;
    margin-top: 2rem;
}

.article-content h1:first-child {
    margin-top: 0;
}

.article-content h2 {
    font-size: 2rem;
    margin-top: 2rem;
    margin-bottom: 1rem;
    border-bottom: 1px solid var(--border);
    padding-bottom: 0.5rem;
}

.article-content h3 {
    font-size: 1.5rem;
    margin-top: 1.5rem;
    margin-bottom: 0.75rem;
}

.article-content p {
    margin-bottom: 1.25rem;
}

.article-content ul,
.article-content ol {
    margin-left: 2rem;
    margin-bottom: 1.25rem;
}

.article-content li {
    margin-bottom: 0.5rem;
}

.article-content table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content th {
    background: var(--bg-secondary);
    padding: 1rem;
    text-align: left;
    font-weight: 600;
    border: 1px solid var(--border);
}

.article-content td {
    padding: 1rem;
    border: 1px solid var(--border);
}

.article-content blockquote {
    margin-left: 0;
    padding-left: 1.5rem;
    border-left: 3px solid var(--accent-blue);
    color: var(--text-secondary);
    font-style: italic;
    margin-bottom: 1.25rem;
}

.article-content hr {
    border: none;
    height: 1px;
    background: var(--border);
    margin: 2rem 0;
}

.article-content code {
    background: var(--bg-card);
    padding: 0.25rem 0.5rem;
    border-radius: 0.25rem;
    font-family: "Courier New", monospace;
    font-size: 0.9em;
    color: var(--accent-cyan);
}

.article-content pre {
    background: var(--bg-card);
    padding: 1.5rem;
    border-radius: 0.5rem;
    overflow-x: auto;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content pre code {
    background: none;
    padding: 0;
    color: var(--text-primary);
}

/* More in Category */
.more-in-category {
    margin-top: 4rem;
    padding-top: 2rem;
    border-top: 1px solid var(--border);
}

.more-in-category h3 {
    font-size: 1.5rem;
    margin-bottom: 2rem;
}

.more-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
    gap: 2rem;
}

.more-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
}

.more-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
}

.more-card h4 {
    font-size: 1.1rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.more-card p {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.more-card a {
    font-weight: 600;
}

/* Footer */
.site-footer {
    background: var(--bg-secondary);
    border-top: 1px solid var(--border);
    padding: 3rem 2rem;
    margin-top: 4rem;
}

.footer-content {
    max-width: 1400px;
    margin: 0 auto;
}

.footer-disclaimer {
    color: var(--text-secondary);
    font-size: 0.9rem;
    margin-bottom: 1.5rem;
}

.footer-links {
    display: flex;
    gap: 2rem;
    flex-wrap: wrap;
    margin-bottom: 1.5rem;
}

.footer-links a {
    color: var(--text-secondary);
    font-size: 0.9rem;
}

.footer-links a:hover {
    color: var(--text-primary);
}

.back-to-top {
    display: none;
    position: fixed;
    bottom: 2rem;
    right: 2rem;
    width: 3rem;
    height: 3rem;
    background: var(--accent-blue);
    border-radius: 50%;
    color: white;
    align-items: center;
    justify-content: center;
    cursor: pointer;
    z-index: 999;
    transition: all 0.3s ease;
}

.back-to-top:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}

.back-to-top.visible {
    display: flex;
}

/* Feedback Widget */
.feedback-widget {
    position: fixed;
    bottom: 2rem;
    left: 2rem;
    z-index: 1000;
}
.feedback-toggle {
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem 1.2rem;
    border-radius: 2rem;
    cursor: pointer;
    font-size: 0.9rem;
    font-weight: 600;
    box-shadow: 0 4px 15px rgba(59,130,246,0.4);
    transition: all 0.3s ease;
}
.feedback-toggle:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}
.feedback-panel {
    display: none;
    position: absolute;
    bottom: 3.5rem;
    left: 0;
    width: 340px;
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 1rem;
    box-shadow: 0 10px 40px rgba(0,0,0,0.3);
    overflow: hidden;
}
.feedback-panel.open {
    display: block;
    animation: feedbackSlideUp 0.25s ease;
}
@keyframes feedbackSlideUp {
    from { opacity: 0; transform: translateY(10px); }
    to { opacity: 1; transform: translateY(0); }
}
.feedback-header {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding: 1rem 1.2rem;
    border-bottom: 1px solid var(--border);
}
.feedback-header h3 {
    margin: 0;
    font-size: 1rem;
    color: var(--text-primary);
}
.feedback-close {
    background: none;
    border: none;
    color: var(--text-muted);
    cursor: pointer;
    font-size: 1.2rem;
    padding: 0;
}
.feedback-form {
    padding: 1rem 1.2rem;
}
.feedback-field {
    margin-bottom: 0.8rem;
}
.feedback-field label {
    display: block;
    font-size: 0.8rem;
    color: var(--text-secondary);
    margin-bottom: 0.3rem;
    font-weight: 600;
}
.feedback-type-btns {
    display: flex;
    gap: 0.5rem;
}
.feedback-type-label {
    display: flex !important;
    align-items: center;
    gap: 0.25rem;
    font-size: 0.8rem !important;
    color: var(--text-primary) !important;
    cursor: pointer;
    padding: 0.3rem 0.6rem;
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    transition: all 0.2s;
}
.feedback-type-label:has(input:checked) {
    border-color: var(--accent-blue);
    background: rgba(59,130,246,0.1);
}
.feedback-type-label input {
    display: none;
}
.feedback-form textarea,
.feedback-form input[type="email"] {
    width: 100%;
    padding: 0.5rem 0.7rem;
    background: var(--background);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 0.85rem;
    font-family: inherit;
    resize: vertical;
    box-sizing: border-box;
}
.feedback-form textarea:focus,
.feedback-form input[type="email"]:focus {
    outline: none;
    border-color: var(--accent-blue);
}
.feedback-submit {
    width: 100%;
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem;
    border-radius: 0.5rem;
    cursor: pointer;
    font-weight: 600;
    font-size: 0.9rem;
    transition: background 0.2s;
}
.feedback-submit:hover {
    background: var(--accent-purple);
}
.feedback-success {
    padding: 2rem;
    text-align: center;
    color: var(--text-secondary);
}

/* Pagination */
.pagination {
    display: flex;
    justify-content: center;
    gap: 0.5rem;
    margin: 3rem 0;
}

.pagination a,
.pagination span {
    padding: 0.75rem 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    transition: all 0.2s ease;
}

.pagination a:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.pagination span.current {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Responsive */
@media (max-width: 768px) {
    .header-inner {
        padding: 1rem;
    }

    .nav-links {
        display: none;
        position: absolute;
        top: 4rem;
        left: 0;
        right: 0;
        background: var(--bg-secondary);
        flex-direction: column;
        gap: 0;
        border-bottom: 1px solid var(--border);
        border-radius: 0;
    }

    .nav-links.active {
        display: flex;
    }

    .nav-links li {
        padding: 1rem;
        border-bottom: 1px solid var(--border);
    }

    .nav-toggle {
        display: flex;
    }

    .hero h1 {
        font-size: 2rem;
    }

    .hero .tagline {
        font-size: 1rem;
    }

    .article-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .entity-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .article-page {
        padding: 1rem;
    }

    .article-content h1 {
        font-size: 1.75rem;
    }

    .article-content h2 {
        font-size: 1.5rem;
    }

    .article-meta-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .search-container {
        padding: 0 1rem;
    }

    .filter-buttons {
        overflow-x: auto;
        padding-bottom: 1rem;
    }

    .share-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .sibling-pills {
        overflow-x: auto;
        padding-bottom: 0.5rem;
    }

    .entity-hero-content {
        flex-direction: column;
        text-align: center;
    }

    .entity-hero-title {
        font-size: 2rem;
    }
}

@media (max-width: 480px) {
    .header-inner {
        padding: 0.75rem;
    }

    .site-logo {
        font-size: 1.2rem;
    }

    .hero h1 {
        font-size: 1.5rem;
    }

    .hero-stats {
        grid-template-columns: 1fr;
    }

    .article-grid {
        gap: 1rem;
    }

    .article-content {
        font-size: 1rem;
    }

    .article-content h1 {
        font-size: 1.5rem;
    }

    .article-content h2 {
        font-size: 1.25rem;
    }

    .article-content h3 {
        font-size: 1.1rem;
    }

    .card-title {
        font-size: 1rem;
    }

    .breadcrumb {
        font-size: 0.8rem;
    }

    .sibling-pill {
        padding: 0.5rem 1rem;
        font-size: 0.85rem;
    }

    .share-btn {
        padding: 0.6rem 1rem;
        font-size: 0.85rem;
    }
}

/* PHASE D1: Newsletter CTA */
.newsletter-cta {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2.5rem;
    text-align: center;
    margin: 3rem 0;
    max-width: 600px;
    margin-left: auto;
    margin-right: auto;
}

.newsletter-cta h3 {
    font-size: 1.5rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.newsletter-cta p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 1rem;
}

.newsletter-cta form {
    display: flex;
    gap: 0.5rem;
    flex-direction: column;
}

.newsletter-cta input {
    padding: 0.75rem 1rem;
    background: var(--bg-primary);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-primary);
    font-size: 1rem;
}

.newsletter-cta input::placeholder {
    color: var(--text-muted);
}

.newsletter-cta button {
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border: none;
    border-radius: 0.25rem;
    font-weight: 600;
    cursor: pointer;
    transition: background 0.2s ease;
}

.newsletter-cta button:hover {
    background: var(--accent-purple);
}

/* PHASE F1: Feedback bar */
.feedback-bar {
    display: flex;
    gap: 2rem;
    justify-content: center;
    padding: 2rem 0;
    border-top: 1px solid var(--border);
    margin-top: 3rem;
    flex-wrap: wrap;
}

.feedback-bar a {
    color: var(--text-secondary);
    font-weight: 500;
    transition: color 0.2s ease;
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
}

.feedback-bar a:hover {
    color: var(--accent-blue);
}

/* PHASE C1: Company view toggles */
.view-toggle-buttons {
    display: flex;
    gap: 1rem;
    justify-content: center;
    margin: 2rem 0;
    flex-wrap: wrap;
}

.view-toggle-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
}

.view-toggle-btn.active {
    background: var(--accent-blue);
    color: white;
    border-color: var(--accent-blue);
}

.view-toggle-btn:hover {
    border-color: var(--accent-blue);
    color: var(--text-primary);
}

.entity-view {
    display: none;
}

.entity-view.active {
    display: block;
}

.sector-group {
    margin-bottom: 3rem;
}

.sector-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

.country-group {
    margin-bottom: 3rem;
}

.country-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

/* Related section for companies */
.related-section {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    margin: 3rem 0;
}

.related-section h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
}

.related-links {
    display: flex;
    flex-direction: column;
    gap: 1rem;
}

.related-links a {
    padding: 1rem;
    background: var(--bg-primary);
    border-radius: 0.25rem;
    color: var(--accent-blue);
    font-weight: 500;
    transition: all 0.2s ease;
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.related-links a:hover {
    background: var(--bg-card-hover);
    color: var(--accent-purple);
}

@media (max-width: 768px) {
    .newsletter-cta {
        padding: 1.5rem;
    }

    .feedback-bar {
        gap: 1rem;
    }

    .view-toggle-buttons {
        gap: 0.5rem;
    }

    .view-toggle-btn {
        padding: 0.6rem 1rem;
        font-size: 0.9rem;
    }
}
</style>
</head>
<body>
    <header class="site-header">
        <div class="header-inner">
            <a href="/" class="site-logo">
                <div class="logo-mark">30</div>
                <div class="logo-text">
                    <div class="logo-text-main">2030</div>
                    <div class="logo-text-sub">Report</div>
                </div>
            </a>
            <nav class="nav-links">
                <li><a href="/">Dashboard</a></li>
                <li><a href="/browse/countries.html">Countries</a></li>
                <li><a href="/browse/companies.html">Companies</a></li>
                <li><a href="/browse/sectors.html">Sectors</a></li>
                <li><a href="/government.html">Government</a></li>
                <li><a href="/search.html">Search</a></li>
                <li><a href="/about.html">About</a></li>
            </nav>
            <button class="nav-toggle" onclick="toggleNav()">
                <span></span>
                <span></span>
                <span></span>
            </button>
        </div>
    </header>

    <main class="article-page">
        <div class="breadcrumb">
            <a href="/">Home</a><span>/</span><a href="/browse/companies.html">Companies</a><span>/</span><a href="/browse/companies/roche.html">Roche</a><span>/</span><span>Analyst</span>
        </div>

        <article class="article-header">
            <div class="article-meta-bar">
                <div class="article-category">
                    <span class="card-badge badge-companies">üè¢ Companies</span>
                    <span class="card-audience">üë§ Analyst</span>
                </div>
                <div class="read-time">‚è±Ô∏è 20 min read</div>
            </div>

            <div class="entity-name-display">üè¢ Roche</div>
            
        <div class="share-bar">
            <span class="share-bar-label">Share:</span>
            <button class="share-btn" onclick="copyLink(event)">üìã Copy Link</button>
            <button class="share-btn" onclick="shareOnTwitter()">ùïè Twitter</button>
            <button class="share-btn" onclick="shareOnLinkedIn()">üíº LinkedIn</button>
            <button class="share-btn" onclick="shareOnFacebook()">üìò Facebook</button>
            <button class="share-btn" onclick="shareOnWhatsApp()">üí¨ WhatsApp</button>
            <button class="share-btn" onclick="shareViaEmail()">‚úâÔ∏è Email</button>
        </div>
        
            
        <div class="sibling-nav">
            <div class="sibling-nav-label">All Perspectives:</div>
            <div class="sibling-pills">
                <div class="sibling-pill "><a href="/articles/companies-europe-roche-roche-ceo.html">CEO</a></div><div class="sibling-pill "><a href="/articles/companies-europe-roche-roche-employee.html">Employee</a></div><div class="sibling-pill active"><a href="/articles/companies-europe-roche-roche-investor.html">Analyst</a></div>
            </div>
        </div>
        

            <div class="article-content">
                <h1>ENTITY: ROCHE HOLDING AG</h1>
<h2>A Macro Intelligence Memo | June 2030 | Investor Edition</h2>
<p><strong>From:</strong> The 2030 Report Global Intelligence Division<br />
<strong>Date:</strong> June 30, 2030<br />
<strong>Re:</strong> Structural Transformation Through AI-Enabled Drug Discovery and Precision Medicine Integration</p>
<hr />
<h2>SUMMARY: THE BEAR CASE vs. THE BULL CASE</h2>
<p><strong>BEAR CASE:</strong><br />
- <strong>Current Stock Price:</strong> CHF 315 (~USD 350/share; June 2030)<br />
- <strong>Bear Thesis:</strong> AI drug discovery productivity gains prove temporary; clinical trial failures increase (batch effects); pricing pressure intensifies (payer pushback); patent expirations accelerate; biosimilar competition compresses margins; regulatory scrutiny increases; organic growth stalls at 0-2%; ROIC compresses to 8-10%<br />
- <strong>Bear Target (2035):</strong> CHF 280-310 (~USD 310-345; flat to -1% downside)<br />
- <strong>Downside Scenario Returns:</strong> -1% to +15% over 5 years (including 2% dividends); market underperformance<br />
- <strong>Positioning:</strong> Hold existing positions; reduce on strength above CHF 350; avoid new positions; monitor R&amp;D productivity metrics</p>
<p><strong>BULL CASE:</strong><br />
- <strong>Management Actions:</strong> AI drug discovery accelerates pipeline (15-20 programs in phase III+ by 2032); launches 5-8 new drugs by 2035 from AI-discovered targets; achieves ROIC of 12-14%; maintains pricing power in precision medicine segments; completes 2-3 strategic acquisitions; increases dividend to 3.5-4.0% yield; initiates ‚Ç¨10-15B buyback<br />
- <strong>Stock Trajectory:</strong> CHF 315 ‚Üí CHF 410 (2032) ‚Üí CHF 550-650 (2035); operating margins expand to 36-38%; organic revenue growth reaches 6-8%<br />
- <strong>Entry Points:</strong> Accumulate on weakness below CHF 290/share; add on recession weakness to CHF 240-260; maintain core position; increase on AI pipeline milestone announcements<br />
- <strong>Bull Case Return:</strong> +75-106% by 2035 (11.5-13% CAGR including 3% dividends); multiple expansion if AI-driven growth sustainability demonstrated</p>
<hr />
<h2>EXECUTIVE SUMMARY</h2>
<p>Roche traded at CHF 315 (approximately $350 USD) in June 2030, representing a market capitalization of $490 billion. This represents a 68% appreciation from the June 2025 baseline of approximately $290 billion market cap. Unlike the AI-beneficiary narrative that drove software companies higher, Roche's appreciation reflects something more fundamental: the structural transformation of pharmaceutical R&amp;D through AI-enabled target identification and lead compound optimization.</p>
<p>This memo examines Roche's transition from traditional pharma company with in-house diagnostics to integrated AI-driven therapeutic discovery and precision medicine platform.</p>
<hr />
<h2>THE BASELINE: PHARMA CHALLENGES IN 2025</h2>
<p>The traditional pharmaceutical industry faced endemic challenges in 2025:</p>
<ul>
<li><strong>R&amp;D productivity crisis</strong>: Average cost per approved drug exceeded $3 billion. Time to approval exceeded 10-12 years.</li>
<li><strong>Patent cliff exposure</strong>: Roche faced $15+ billion in annual revenue exposure from maturing blockbuster expirations (Rituxan, Herceptin, Avastin).</li>
<li><strong>Personalized medicine complexity</strong>: Companion diagnostic requirements created smaller addressable markets and higher development costs.</li>
<li><strong>Regulatory scrutiny</strong>: Increasing pressure on drug pricing, particularly from U.S. governments and payers.</li>
</ul>
<p>Roche's growth rate decelerated to 2-4% annually. Acquisitions provided revenue lift (Spark Therapeutics, Carmot) but did not solve the fundamental productivity problem.</p>
<p>The consensus among pharmaceutical analysts was grim: big pharma faced secular decline as drug development became too expensive, regulatory environment became too hostile, and pricing pressure intensified.</p>
<hr />
<h2>THE INFLECTION: AI-DRIVEN TARGET IDENTIFICATION</h2>
<p>The transformer-based AI models that revolutionized language understanding in 2022-2024 found unexpected application in protein structure prediction and drug discovery. By 2026-2027, companies like DeepMind, Structure Prediction Consortium members, and specialized biotech platforms demonstrated that AI could:</p>
<ol>
<li><strong>Predict protein structures</strong> from amino acid sequences (solving 30-year-old problem in 18 months)</li>
<li><strong>Identify novel drug targets</strong> by analyzing disease mechanisms at molecular level</li>
<li><strong>Optimize lead compounds</strong> for efficacy, safety, and manufacturability</li>
<li><strong>Predict clinical trial outcomes</strong> with 60-75% accuracy</li>
</ol>
<p>This was not incremental improvement. This was paradigm shift.</p>
<p>Roche recognized the opportunity early. In 2027, the company initiated:<br />
- <strong>Strategic partnerships</strong> with AI research labs (DeepMind Health, AlphaMissense collaboration expansion)<br />
- <strong>Internal AI capability building</strong> through hiring and acquisition of computational scientists<br />
- <strong>Integration of AI into R&amp;D pipeline</strong>: 40% of new programs initiated in 2027-2028 incorporated AI target discovery</p>
<hr />
<h2>R&amp;D PRODUCTIVITY TRANSFORMATION: 2028-2030</h2>
<p>The results proved transformative:</p>
<p><strong>Target Identification Timeline</strong>: Compressed from 3-5 years to 6-18 months<br />
<strong>Lead Optimization Duration</strong>: Reduced from 4-7 years to 18-36 months<br />
<strong>Preclinical-to-IND Success Rate</strong>: Improved from 25% to 52%<br />
<strong>Cost per Approved Drug (Projected)</strong>: Expected to decline from $3B to $1.2-1.5B</p>
<p>By June 2030, Roche's R&amp;D productivity had accelerated:<br />
- <strong>Pipeline advancement</strong>: 23 new programs entered Phase 1 or Phase 2 in 2029 (vs. 8-10 historical average)<br />
- <strong>Efficacy improvements</strong>: AI-optimized compounds showed 35-50% improvement in efficacy metrics vs. earlier generation drugs<br />
- <strong>Safety optimization</strong>: Reduced clinical safety signals in Phase 2 programs through AI-predicted toxicity models<br />
- <strong>Cost reduction</strong>: R&amp;D spend as percentage of revenue decreased from 19% to 17% while pipeline volume doubled</p>
<hr />
<h2>ONCOLOGY &amp; PRECISION MEDICINE RENAISSANCE</h2>
<p>Roche's oncology franchise, built on Herceptin, Rituxan, and Avastin, faced extinction as patents expired. AI-enabled target discovery catalyzed second renaissance:</p>
<p><strong>2029-2030 Pipeline Highlights</strong>:<br />
- 8 new AI-discovered oncology targets in Phase 2-3<br />
- Companion diagnostics AI-matched to each target<br />
- Projected 2030-2035 launch cadence: 2-3 new oncology products annually</p>
<p><strong>Addressable Market Impact</strong>: Rather than declining as older products lost exclusivity, Roche's oncology revenue stabilized at $18-20B annually (2029-2030 levels) with expectation of 4-6% annual growth through next decade from new AI-enabled products.</p>
<p><strong>Margin Profile</strong>: AI-enabled development reduced per-indication development costs, improving net present value of new programs by 35-40%.</p>
<hr />
<h2>DIAGNOSTICS &amp; PRECISION MEDICINE INTEGRATION</h2>
<p>Roche's diagnostics division, historically viewed as business-unit adjacent to pharma, became strategically central:</p>
<p><strong>The Integration</strong>: AI models trained on Roche's proprietary diagnostic datasets (from cobas analyzers, sequencing platforms, and clinical partnerships) generated insights about disease progression, patient stratification, and treatment response.</p>
<p><strong>Competitive Advantage</strong>: Unlike pure pharma companies, Roche possessed:<br />
- Real-world patient outcome data (from diagnostic results)<br />
- Companion diagnostic capabilities (cobas platforms could validate AI-predicted biomarkers)<br />
- Patient identification infrastructure (diagnostic networks provided access to test populations)</p>
<p><strong>Revenue Impact</strong>: Diagnostics revenue accelerated from 3-4% annual growth to 8-10% growth through:<br />
- Higher-margin companion diagnostics attached to new therapeutic launches<br />
- Standalone AI-powered diagnostic panels predicting disease progression<br />
- Subscription diagnostic models for chronic disease monitoring</p>
<p>By June 2030, diagnostics contributed 35% of total revenue but 42% of profit due to superior margins.</p>
<hr />
<h2>PARTNERSHIPS &amp; ECOSYSTEM STRATEGY</h2>
<p>Rather than building all AI capabilities internally, Roche established an ecosystem of partnerships:</p>
<p><strong>Academic Partnerships</strong>:<br />
- MIT, Stanford, ETH Zurich: computational drug discovery collaboration<br />
- Academic Biotech: DeepMind Health, UC Berkeley, Cambridge</p>
<p><strong>Biotech Partnerships</strong>:<br />
- Carmot Therapeutics: AI-accelerated drug discovery<br />
- Schrodinger: computational chemistry and molecular modeling<br />
- Recursion: phenotypic screening and AI integration</p>
<p><strong>Technology Partnerships</strong>:<br />
- Google Cloud: infrastructure and ML model development<br />
- Nvidia: computing architecture for molecular simulations<br />
- IBM: quantum computing exploration for drug discovery</p>
<p><strong>Acquisition Strategy</strong>:<br />
- Acquired 2 AI-focused biotech companies (2028-2029) for $4.2B combined<br />
- Minority investments in 15+ early-stage AI-drug discovery companies<br />
- R&amp;D spending on AI partnerships: $2.8B in 2029</p>
<p>This ecosystem approach provided:<br />
- Access to cutting-edge computational approaches without building internally<br />
- Risk diversification across multiple AI methodologies<br />
- Optionality to acquire successful approaches before commercialization</p>
<hr />
<h2>FINANCIAL IMPACT: 2025 VS. 2030</h2>
<p><strong>Revenue Growth</strong>:<br />
- 2025: CHF 69.8 billion<br />
- 2030: CHF 84.2 billion (20.6% total growth, 3.9% CAGR)<br />
- Growth acceleration: 2025-2027 (2.1% CAGR) ‚Üí 2028-2030 (6.8% CAGR)</p>
<p><strong>R&amp;D Spend</strong>:<br />
- 2025: CHF 13.2B (18.9% of revenue)<br />
- 2030: CHF 14.3B (17.0% of revenue)<br />
- Improved productivity despite higher absolute investment</p>
<p><strong>Operating Margin</strong>:<br />
- 2025: 32.1%<br />
- 2030: 36.8%<br />
- Driver: revenue growth outpacing cost increases due to R&amp;D efficiency</p>
<p><strong>Drug Launch Cadence</strong>:<br />
- 2025-2027: average 1.2 new approvals annually<br />
- 2028-2030: average 2.7 new approvals annually<br />
- Expected 2031-2035: 3-4 approvals annually</p>
<hr />
<h2>THE VALUATION THESIS</h2>
<p>Roche's June 2030 valuation of $490B reflects:</p>
<p><strong>Bear Case ($280B)</strong>: AI benefits partially unrealized; regulatory environment deteriorates; patent cliff still significant<br />
- Assumes 2.5% revenue CAGR through 2035<br />
- Operating margins compress to 31% due to pricing pressure<br />
- Terminal value assumes 1% perpetual growth</p>
<p><strong>Base Case ($490B)</strong>: AI-enabled productivity sustained; new pipeline delivers; diagnostics integration continues<br />
- Assumes 5-6% revenue CAGR through 2035<br />
- Operating margins expand to 39% as R&amp;D leverage improves<br />
- Terminal value assumes 2.5% perpetual growth</p>
<p><strong>Bull Case ($650B)</strong>: AI breakthrough in early-stage development; multiple first-in-class approvals; precision medicine becomes major revenue driver<br />
- Assumes 7-8% revenue CAGR through 2035<br />
- Operating margins reach 42% through R&amp;D leverage and diagnostic mix<br />
- Terminal value assumes 3% perpetual growth</p>
<p>Current market valuation appears consistent with base case. Upside exists if AI-driven productivity improvements exceed current projections.</p>
<hr />
<h2>KEY RISKS &amp; MITIGANTS</h2>
<p><strong>Risk 1: AI Drug Efficacy Overestimation</strong><br />
- AI models predict efficacy but clinical reality often disappoints<br />
- Mitigation: Roche has adopted conservative efficacy assumptions; early Phase 2 data confirms predictions<br />
- Assessment: MODERATE RISK, manageable through conservative underwriting</p>
<p><strong>Risk 2: Regulatory Skepticism of AI-Designed Drugs</strong><br />
- FDA and EMA may require additional data to approve AI-optimized compounds<br />
- Mitigation: Proactive regulatory engagement; early Phase 2 safety data very favorable<br />
- Assessment: LOW RISK, regulators are pragmatic about productive approaches</p>
<p><strong>Risk 3: Patent Cliff Acceleration</strong><br />
- Older products (Herceptin, Rituxan) may lose exclusivity faster than expected<br />
- Mitigation: New pipeline launch cadence of 2-3 annually should offset<br />
- Assessment: MANAGEABLE, mitigated by pipeline acceleration</p>
<p><strong>Risk 4: Pricing Pressure Intensification</strong><br />
- U.S. drug pricing legislation; international payer pressure<br />
- Mitigation: Diagnostic-linked therapeutics support premium pricing; therapeutic improvements justify pricing<br />
- Assessment: MODERATE RISK, hedged by improved clinical value proposition</p>
<p><strong>Risk 5: Competitive Catch-Up</strong><br />
- Other pharma companies (Pfizer, Merck, GSK) adopting similar AI strategies<br />
- Mitigation: Roche's diagnostic advantage and integrated platform provide 2-3 year lead<br />
- Assessment: LONG-TERM RISK, manageable through continued innovation investment</p>
<hr />
<h2>SECTION 7: COMPETITIVE LANDSCAPE AND PHARMA INDUSTRY CONTEXT</h2>
<h3>How Roche Compares to Pharma Peers on AI Integration</h3>
<p>Roche's AI advantage is not absolute. Competitors are adopting similar strategies:</p>
<p><strong>Merck (MSD):</strong><br />
- AI partnerships: Schrodinger, DeepMind partnerships (similar to Roche)<br />
- Pipeline acceleration: 8-10 new programs annually (vs. Roche 23)<br />
- Diagnostic advantage: Minimal (lacks Roche's diagnostic integration)<br />
- Assessment: Following Roche's strategy but 2-3 years behind</p>
<p><strong>Pfizer:</strong><br />
- AI partnerships: Limited compared to Roche/Merck<br />
- Historical focus: Acquisition-driven growth (Seagen, Arena) rather than internal R&amp;D<br />
- Diagnostic advantage: Minimal<br />
- Assessment: Slower to adopt AI strategy; focus remains acquisition-driven</p>
<p><strong>GSK:</strong><br />
- AI partnerships: Moderate (focused on oncology)<br />
- Recent restructuring: Separated pharma/vaccines/consumer health (2021), impacting R&amp;D<br />
- Diagnostic advantage: Developing but not integrated<br />
- Assessment: Rebuilding; significant pipeline risk</p>
<p><strong>Novo Nordisk:</strong><br />
- AI focus: Moderate (focused on GLP-1 receptor agonists)<br />
- Advantage: Dominant position in obesity/diabetes (AI augmenting existing franchise)<br />
- Diagnostic advantage: Minimal<br />
- Assessment: Leveraging existing dominance; not pioneering AI use</p>
<p><strong>Roche's Advantage Summary:</strong><br />
1. First-mover advantage in AI-pharma integration (2-3 year lead)<br />
2. Unique diagnostic-therapeutic integration advantage<br />
3. Superior pipeline acceleration (23 programs vs. 8-15 competitors)<br />
4. Demonstrated efficacy translation (Phase 2 data supporting AI predictions)</p>
<hr />
<h2>SECTION 8: THE PRECISION MEDICINE THESIS AND MARKET SIZE</h2>
<h3>Market Opportunity from AI-Enabled Precision Medicine</h3>
<p>AI-enabled precision medicine creates new addressable markets:</p>
<p><strong>Precision Medicine Market Expansion:</strong><br />
- 2025: Global precision medicine market: $245 billion (10-15% of total pharma market)<br />
- 2030: Estimated $580 billion (18-22% of total pharma market)<br />
- CAGR: 18-20%</p>
<p><strong>Roche's Positioning:</strong><br />
Roche, with AI-enhanced target discovery + integrated diagnostics, is uniquely positioned to capture premium in precision medicine markets:</p>
<p><strong>Example: AI-Discovered Oncology Biomarker-Driven Treatment</strong><br />
- Traditional oncology drug development: $3B cost, 10-12 year timeline, 25% approval rate<br />
- Precision medicine approach: $1.2B cost, 7-8 year timeline, 45% approval rate<br />
- Roche's potential annual launch cadence: 2-3 products/year (vs. 1-2 historically)</p>
<p>This represents structural improvement in industry productivity, with Roche positioned to capture disproportionate share.</p>
<hr />
<h2>SECTION 9: MANUFACTURING AND SUPPLY CHAIN IMPLICATIONS</h2>
<h3>AI-Optimized Manufacturing</h3>
<p>Beyond R&amp;D, AI-optimized compounds have manufacturing implications:</p>
<p><strong>Compound Design for Manufacturability:</strong><br />
AI models now optimize compounds not just for efficacy/safety but also manufacturability:<br />
- Reduced synthesis steps: 35-40% reduction in manufacturing complexity<br />
- Improved yield: Higher manufacturing yields improve economics<br />
- Cost reduction: Manufacturing cost per unit declining 15-20%</p>
<p><strong>Supply Chain Implications:</strong><br />
- Roche manufacturing footprint optimization (consolidating inefficient plants)<br />
- Contract manufacturing relationships (more attractive due to AI-simplified synthesis)<br />
- Raw material supply optimization (AI predicting demand, reducing inventory)</p>
<p><strong>Financial Impact:</strong><br />
Manufacturing efficiency improvements contribute 15-20% of the overall gross margin improvement Roche has achieved 2025-2030.</p>
<hr />
<h2>SECTION 10: REGULATORY AND POLICY ENVIRONMENT</h2>
<h3>FDA and EMA Reception of AI-Designed Drugs</h3>
<p><strong>Current Regulatory Status (June 2030):</strong><br />
- FDA approved first AI-designed drug (Roche, 2029): Set precedent<br />
- EMA approved second AI-designed drug (GSK, 2030): Validation of regulatory pathway<br />
- Regulatory guidance: FDA issued draft guidance on AI-drug approval (January 2029)</p>
<p><strong>Regulatory Acceptance Factors:</strong><br />
1. <strong>Efficacy Data:</strong> Early Phase 2/3 data for AI-designed compounds exceeded predictions (reducing regulatory skepticism)<br />
2. <strong>Safety Profile:</strong> AI-predicted safety signals validated in clinical practice<br />
3. <strong>Mechanistic Understanding:</strong> AI models now provide mechanistic explanations (reducing "black box" concerns)<br />
4. <strong>Transparency:</strong> Roche/others providing detailed AI methodology documentation (addressing regulatory concerns)</p>
<p><strong>Potential Regulatory Headwinds:</strong><br />
- Right-to-explanation requirements (EU): Could require AI model interpretability (achievable but costly)<br />
- Extended review timelines: Some regulators requesting additional AI validation data<br />
- Liability questions: Who is responsible if AI-designed drug has unexpected adverse events? (Not yet resolved)</p>
<p><strong>Assessment:</strong> Regulatory environment appears favorable; AI drugs receiving faster approval paths than traditional approaches.</p>
<hr />
<h2>SECTION 11: LONG-TERM STRATEGIC POSITIONING (2030-2040)</h2>
<h3>Roche's Path to Become an Integrated Pharma-Diagnostics-AI Company</h3>
<p>Roche's strategy through 2040 is to become increasingly integrated diagnostics-therapeutics company powered by AI:</p>
<p><strong>Strategic Vision Elements:</strong></p>
<p><strong>1. AI-Enabled Drug Discovery as Core Competency:</strong><br />
- By 2035: 80% of new programs should incorporate AI target discovery<br />
- By 2040: AI-native drug development becoming standard (not outlier)</p>
<p><strong>2. Diagnostic Integration Deepening:</strong><br />
- Real-world evidence: Using diagnostic networks to monitor treatment outcomes and generate new insights<br />
- Biomarker development: AI-identified biomarkers for patient stratification<br />
- Subscription diagnostics: Chronic disease monitoring becoming revenue stream</p>
<p><strong>3. Platform Leveraging:</strong><br />
- Target and biomarker libraries: Leverage AI-discovered targets across multiple indications<br />
- Therapeutic platform: Leverage successful drug mechanisms across patient populations<br />
- Competitive moat: Integrated pharma-diagnostics-AI platform difficult to replicate</p>
<p><strong>4. M&amp;A Strategy Implications:</strong><br />
- Continued acquisition of AI/biotech companies for capability building<br />
- Integration of acquired companies into Roche AI platform<br />
- Selective divestitures of non-strategic assets (legacy diagnostics, standalone drugs)</p>
<p><strong>Competitive Moat Evolution:</strong><br />
By 2040, Roche's integrated diagnostics-therapeutics-AI platform would create durable competitive advantage difficult for pure pharma companies to replicate.</p>
<hr />
<h2>SECTION 12: ESG AND SUSTAINABILITY CONSIDERATIONS</h2>
<h3>Pharma Industry ESG Pressures and Roche's Response</h3>
<p>Pharmaceutical industry faces increasing ESG scrutiny:</p>
<p><strong>Drug Pricing Pressure (E&amp;S):</strong><br />
- Global criticism of high drug prices (particularly US market)<br />
- International negotiation on pricing (EU, Japan, Australia all negotiating lower prices)<br />
- Potential regulatory pricing controls in US (still debated politically)</p>
<p><strong>Roche's Response:</strong><br />
- AI-enabled drug development reducing per-drug development cost (enabling lower pricing while maintaining margins)<br />
- Diagnostics enabling personalized medicine (narrower patient populations but higher efficacy, justifying premium pricing)<br />
- Commitment to reducing drug access barriers in emerging markets</p>
<p><strong>Environmental Considerations:</strong><br />
- Green chemistry: AI-optimized compounds reducing manufacturing waste (supporting environmental goals)<br />
- Clinical trial efficiency: Faster AI-driven development reducing environmental footprint of extended trial periods<br />
- Manufacturing efficiency: AI-driven supply chain optimization reducing carbon footprint</p>
<p><strong>Governance Considerations:</strong><br />
- Board diversity: Roche pursuing pharmaceutical industry-standard diversity targets<br />
- Executive compensation: Tying compensation to R&amp;D productivity metrics (including AI effectiveness)<br />
- Transparency: Detailed disclosure of AI methodologies and outcomes</p>
<p><strong>Assessment:</strong> Roche's AI-driven strategy aligns well with ESG objectives (cost reduction, environmental efficiency, governance transparency). This creates positive ESG narrative for investors.</p>
<hr />
<h2>SECTION 13: VALUATION SENSITIVITY ANALYSIS</h2>
<h3>Key Drivers of Roche Valuation</h3>
<p><strong>Primary Value Drivers:</strong><br />
1. Pipeline launch cadence: Each year of delay in pipeline launches reduces valuation ~CHF 15-20B<br />
2. Operating margin expansion: Each 1% margin expansion worth ~CHF 8-10B in valuation<br />
3. Patent cliff management: Ability to offset patent losses with new launches critical<br />
4. Diagnostic revenue growth: Each 1% improvement in diagnostic growth rate adds ~CHF 3-5B to valuation</p>
<p><strong>Valuation Sensitivity to Key Assumptions:</strong></p>
<p><strong>Scenario: Pipeline Acceleration Slower Than Projected</strong><br />
- If actual pipeline deliveries 20% below projections: Fair value reduces to CHF 380-400</p>
<p><strong>Scenario: Patent Cliff More Severe Than Expected</strong><br />
- If Rituxan/Herceptin/Avastin lose exclusivity 18 months earlier than expected: Fair value reduces to CHF 420-450</p>
<p><strong>Scenario: Diagnostic Integration Exceeds Projections</strong><br />
- If diagnostic revenue CAGR reaches 12% (vs. 8-10% projected): Fair value increases to CHF 540-580</p>
<p><strong>Scenario: Pharma Industry Pricing Pressure Intensifies</strong><br />
- If drug pricing legislation passes with significant pricing controls: Fair value reduces to CHF 350-380</p>
<h3>THE BULL CASE ALTERNATIVE: Precision Medicine Dominance and AI-Driven Operating Leverage</h3>
<p>The bull case rests on three critical pillars: (1) pipeline acceleration exceeding current projections with 4-5 new drug launches annually by 2033-2035 (vs. 2-3 base case), driven by AI-enabled target discovery proving more productive than historical rates, generating USD 8-12 billion in incremental peak sales; (2) diagnostic integration expanding faster than base case, with subscription diagnostic models for chronic disease monitoring reaching USD 3-4 billion annual revenue by 2035 (vs. USD 1-2 billion base case); (3) operating margin expansion to 42-44% through superior R&amp;D leverage (declining R&amp;D as percentage of revenue to 14-15%), therapeutic mix optimization, and precision medicine pricing power justification.</p>
<p>Under bull case assumptions, Roche's 2035 revenue reaches CHF 110-120 billion (vs. CHF 100-105 billion base case), operating margin reaches 42-44%, and enterprise value approaches CHF 750-850 billion (vs. CHF 650-700 billion base case). Bull case entry points below CHF 290/share with accumulation targets on recession weakness to CHF 240-260/share. Bull case probability: 30%.</p>
<hr />
<h2>THE DIVERGENCE: BEAR vs. BULL INVESTMENT OUTCOMES</h2>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Bear Case</th>
<th>Base Case</th>
<th>Bull Case</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2035 Revenue (CHF billions)</strong></td>
<td>92-98</td>
<td>100-105</td>
<td>110-120</td>
</tr>
<tr>
<td><strong>Revenue CAGR 2030-2035</strong></td>
<td>2.5%</td>
<td>5-6%</td>
<td>7-8%</td>
</tr>
<tr>
<td><strong>2035 Operating Margin</strong></td>
<td>31-33%</td>
<td>39%</td>
<td>42-44%</td>
</tr>
<tr>
<td><strong>New Drug Launch Cadence (2035)</strong></td>
<td>1.5-2.0 annually</td>
<td>2.5-3.0 annually</td>
<td>4-5 annually</td>
</tr>
<tr>
<td><strong>Patent Cliff Impact</strong></td>
<td>Severe (revenue decline 15%+)</td>
<td>Moderate (offset by new launches)</td>
<td>Minimal (new launches exceed losses)</td>
</tr>
<tr>
<td><strong>AI Pipeline Productivity</strong></td>
<td>Below expectations; slower efficacy translation</td>
<td>On-track; efficacy validates; 80%+ success rate</td>
<td>Exceeds expectations; efficacy superior to traditional approaches</td>
</tr>
<tr>
<td><strong>Diagnostic Revenue (2035)</strong></td>
<td>CHF 18-20B (low-single digit growth)</td>
<td>CHF 22-24B (8-10% growth)</td>
<td>CHF 28-32B (12-15% growth)</td>
</tr>
<tr>
<td><strong>R&amp;D as % of Revenue</strong></td>
<td>18-20% (productivity gains lost)</td>
<td>16-17%</td>
<td>14-15%</td>
</tr>
<tr>
<td><strong>Precision Medicine Market Capture</strong></td>
<td>12-15%</td>
<td>20-25%</td>
<td>30-35%</td>
</tr>
<tr>
<td><strong>Operating Leverage (6-year margin expansion)</strong></td>
<td>-1 to +1 percentage point</td>
<td>+2.5 to +3.0 pp</td>
<td>+4.5 to +5.5 pp</td>
</tr>
<tr>
<td><strong>2035 Enterprise Value (CHF billions)</strong></td>
<td>580-620</td>
<td>650-700</td>
<td>780-850</td>
</tr>
<tr>
<td><strong>Price Target (CHF per share)</strong></td>
<td>340-380</td>
<td>420-480</td>
<td>540-620</td>
</tr>
<tr>
<td><strong>% Return vs June 2030 (CHF 315)</strong></td>
<td>+8 to +20%</td>
<td>+33 to +52%</td>
<td>+71 to +97%</td>
</tr>
<tr>
<td><strong>Annual Return (5-year CAGR)</strong></td>
<td>+1.5%</td>
<td>+6.0%</td>
<td>+11.5%</td>
</tr>
<tr>
<td><strong>5-Year Total Return (including 2% dividend)</strong></td>
<td>+8%</td>
<td>+33%</td>
<td>+77%</td>
</tr>
</tbody>
</table>
<p><strong>Probability-Weighted Valuation (2035):</strong><br />
- Bull case (30% probability) √ó CHF 580 = CHF 174<br />
- Base case (50% probability) √ó CHF 450 = CHF 225<br />
- Bear case (20% probability) √ó CHF 360 = CHF 72<br />
- <strong>Probability-Weighted Fair Value (2035): CHF 471 per share</strong><br />
- <strong>Implied 5-year CAGR return: +8.4% annually</strong></p>
<p><strong>Current Market Assessment (June 2030):</strong><br />
- Current price: CHF 315/share<br />
- Implied 2035 fair value (PW): CHF 471<br />
- <strong>Implied return: +49.5% over 5 years, or +8.4% CAGR</strong><br />
- <strong>Valuation: Moderately undervalued (20% discount to fair value)</strong></p>
<p><strong>Investment Implication:</strong><br />
Roche at CHF 315 (June 2030) appears modestly undervalued relative to probability-weighted DCF analysis, offering 8-9% annual returns under base case execution and 11-12% under bull case scenarios. The bull case upside (77% total return) reflects successful pipeline acceleration, superior AI productivity, and precision medicine market dominance. Bear case downside (8% total return) is limited due to defensive pharmaceutical positioning and dividend income (2%+ yield).</p>
<p>Roche is attractive for diversified investors seeking: (1) pharmaceutical sector exposure with structural growth through AI, (2) defensive characteristics during economic slowdowns, (3) dividend income (2.5-3.0% yield), (4) precision medicine megatrend exposure, (5) reduced valuation risk vs. pure AI software companies.</p>
<p><strong>Rating adjustment: BUY with target price CHF 450-500 (2032) and CHF 520-580 (2035).</strong></p>
<hr />
<h2>INVESTMENT RECOMMENDATION</h2>
<p>Roche represents a rare combination: traditional pharmaceutical company that has successfully leveraged AI to address endemic industry challenges and transformed business model through diagnostics integration.</p>
<p>The transformation is:<br />
- <strong>Structural, not cyclical</strong>: Drug development productivity gains are fundamentally improving pharmaceutical economics<br />
- <strong>Competitive, not generic</strong>: Roche's diagnostics integration and pipeline acceleration create differentiation difficult to replicate<br />
- <strong>De-risked, not speculative</strong>: Early Phase 2 pipeline data validates AI-predicted efficacy and safety profiles</p>
<p><strong>Recommendation: OVERWEIGHT</strong></p>
<p>At CHF 315, Roche deserves premium valuation relative to pharma peers. The company has solved the endemic R&amp;D productivity problem through AI, positioned itself to dominate precision medicine segment, and maintained financial discipline through execution.</p>
<p><strong>Target Price (2032): CHF 420-450</strong><br />
<strong>Target Price (2035): CHF 520-580</strong><br />
<strong>Risk Rating: MODERATE</strong></p>
<p><strong>Bull Case (40% probability):</strong> Pipeline delivers on schedule; diagnostic revenue accelerates; Roche captures 25-30% of precision medicine market growth. Target: CHF 540-600.</p>
<p><strong>Base Case (50% probability):</strong> Pipeline delivers with modest delays; diagnostic integration continues steadily; Roche captures 20-25% of precision medicine growth. Target: CHF 420-480.</p>
<p><strong>Bear Case (10% probability):</strong> Significant pipeline delays; pricing pressure intensifies; competitive catch-up faster than expected. Target: CHF 280-320.</p>
<p>The primary upside driver is pipeline execution. The primary downside risk is slower-than-expected efficacy translation from AI predictions to clinical reality. Current valuation fairly prices base case with meaningful upside to bull case.</p>
<hr />
<p><strong>THE 2030 REPORT</strong><br />
<strong>June 30, 2030</strong><br />
<strong>CONFIDENTIAL ‚Äî INSTITUTIONAL INVESTORS ONLY</strong></p>
<h2>REFERENCES &amp; DATA SOURCES</h2>
<ol>
<li>Bloomberg (Q2 2030): "Roche Q2 2030 Earnings: AI-Driven Drug Discovery and Diagnostics"</li>
<li>McKinsey &amp; Company (2030): "AI in Pharmaceutical Development: Drug Discovery Acceleration"</li>
<li>Reuters (2029): "Pharmaceutical Industry AI Investment and Clinical Trial Efficiency"</li>
<li>Morgan Stanley Healthcare Research (June 2030): "Large-Cap Pharma Valuations and Innovation"</li>
<li>Gartner (2029): "Healthcare AI and Precision Medicine Applications"</li>
<li>Goldman Sachs (2030): "Pharmaceutical Sector Technology and Competitive Advantage"</li>
<li>S&amp;P Global (2030): "Pharma Industry Profitability and R&amp;D Efficiency"</li>
<li>Deloitte (2030): "Pharmaceutical Industry Digital Transformation"</li>
<li>Boston Consulting Group (2030): "Biopharma and Digital Innovation"</li>
<li>Tufts Center for the Study of Drug Development (2030): "Clinical Development Productivity"</li>
<li>Nature Biotechnology (2030): "AI Applications in Drug Discovery"</li>
<li>EvaluatePharma (2030): "Pharma Company Innovation and Valuation Metrics"</li>
</ol>
<hr />
<h2>WHAT YOU SHOULD DO NOW</h2>
<p>The investment landscape described in this memo creates clear winners and losers. Here's how to position yourself:</p>
<p><strong>Immediate portfolio review:</strong> Evaluate your holdings against the bear case scenarios described above. Companies with high labor costs, low AI adoption, and reactive management are value traps, not value investments.</p>
<p><strong>AI transformation screening:</strong> For every company in your portfolio, answer three questions: (1) Has the CEO publicly committed to AI transformation with specific capital allocation? (2) Is the company investing 3%+ of revenue in AI capabilities? (3) Does the company have a credible plan for workforce transition? If the answer to all three is no, consider your exit timeline.</p>
<p><strong>Sector allocation:</strong> Overweight sectors where AI creates new value (healthcare AI, AI infrastructure, AI-enabled services). Underweight sectors where AI primarily destroys existing value without creating new revenue streams.</p>
<p><strong>Geographic diversification:</strong> Countries with proactive AI policies, strong education systems, and flexible labor markets will outperform. Evaluate your geographic exposure accordingly.</p>
<p><strong>Due diligence upgrade:</strong> Add AI readiness assessment to your standard due diligence process. Ask management teams specifically about their AI strategy, timeline, and capital commitment. Vague answers are a red flag.</p>
<p><em>Read more: Browse all <a href="/browse/countries.html">Investor-focused memos</a> across 34 countries and <a href="/browse/companies.html">141 companies</a> for company-specific and country-specific investment analysis.</em></p>
            </div>
        </article>

        <div style="margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); text-align: center;"><a href="/browse/companies/roche.html" style="display: inline-block; padding: 1rem 2rem; background: var(--bg-card); border: 1px solid var(--border); border-radius: 0.5rem; color: var(--text-primary); font-weight: 600; transition: all 0.2s ease;">‚Üê All Roche Articles</a></div>
        
        <div class="more-in-category">
            <h3>More in Companies</h3>
            <div class="more-grid">
                
            <div class="more-card">
                <h4>ENTITY: APPLE CORPORATION</h4>
                <p>FROM: The 2030 Report, Technology & Market Analysis Division</p>
                <a href="/articles/companies-us-apple-apple-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>From: The 2030 Report Global Intelligence Division</p>
                <a href="/articles/companies-us-apple-apple-investor.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>---</p>
                <a href="/articles/companies-us-apple-apple-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: THE HOME DEPOT INC.</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>HOME DEPOT: WORKFORCE RESTRUCTURING IN HOUSING DOWNTURN</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: Home Depot, Inc. | Housing Market Downturn and Structural Retail Transformation</h4>
                <p>FROM: The 2030 Report | Retail and Consumer Spending Analysis</p>
                <a href="/articles/companies-us-home-depot-home-depot-investor.html">Read more ‚Üí</a>
            </div>
            
            </div>
        </div>
        

        <!-- Feedback Widget -->
        <div class="feedback-widget" id="feedbackWidget">
            <button class="feedback-toggle" onclick="toggleFeedback()" aria-label="Report an issue or send feedback">
                üí¨ Feedback
            </button>
            <div class="feedback-panel" id="feedbackPanel">
                <div class="feedback-header">
                    <h3>Send Feedback</h3>
                    <button class="feedback-close" onclick="toggleFeedback()">‚úï</button>
                </div>
                <form class="feedback-form" id="feedbackForm" onsubmit="submitFeedback(event)">
                    <input type="hidden" name="page_url" id="feedbackPageUrl">
                    <div class="feedback-field">
                        <label>Type</label>
                        <div class="feedback-type-btns">
                            <label class="feedback-type-label"><input type="radio" name="type" value="Error" required> üêõ Error</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Suggestion"> üí° Suggestion</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Other"> üìù Other</label>
                        </div>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackMsg">Message</label>
                        <textarea id="feedbackMsg" name="message" rows="3" placeholder="Tell us what's wrong or how we can improve..." required></textarea>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackEmail">Your Email (optional)</label>
                        <input type="email" id="feedbackEmail" name="email" placeholder="your@email.com">
                    </div>
                    <button type="submit" class="feedback-submit">Send Feedback</button>
                </form>
                <div class="feedback-success" id="feedbackSuccess" style="display:none;">
                    <div style="font-size:2rem;">‚úÖ</div>
                    <p>Thank you! Your email client will open with the feedback.</p>
                </div>
            </div>
        </div>

    </main>

    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-disclaimer">
                <strong>Disclaimer:</strong> This report provides forecasts and analysis of AI disruption trends. Predictions are based on current data and expert analysis but are subject to change. Use this information for informational purposes only.
            </div>
            <div class="footer-links">
                <a href="/">Home</a>
                <a href="/browse/countries.html">Countries</a>
                <a href="/browse/companies.html">Companies</a>
                <a href="/browse/sectors.html">Sectors</a>
                <a href="/government.html">Government</a>
                <a href="/press.html">Press</a>
                <a href="/about.html">About</a>
            </div>
            <div style="color: var(--text-muted); font-size: 0.85rem; margin-top: 1rem;">
                &copy; 2030 Intelligence Report. All rights reserved.
            </div>
        </div>
    </footer>

    <button class="back-to-top" onclick="scrollToTop()" title="Back to top">‚Üë</button>

    <script>
        function toggleNav() {
            const navLinks = document.querySelector('.nav-links');
            navLinks.classList.toggle('active');
        }
        // Highlight active nav item
        document.querySelectorAll('.nav-links a').forEach(link => {
            const href = link.getAttribute('href');
            const path = window.location.pathname;
            if (href === '/' && path === '/') link.classList.add('nav-active');
            else if (href !== '/' && path.startsWith(href.replace('.html', ''))) link.classList.add('nav-active');
        });

        function scrollToTop() {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }

        function copyLink(e) {
            const url = window.location.href;
            const btn = e.currentTarget;
            navigator.clipboard.writeText(url).then(() => {
                const originalText = btn.innerText;
                btn.innerText = '‚úì Copied!';
                btn.classList.add('copied');
                setTimeout(() => {
                    btn.innerText = originalText;
                    btn.classList.remove('copied');
                }, 2000);
            });
        }

        const pageTitle = document.title.split(' - ')[0];

        function shareOnTwitter() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://twitter.com/intent/tweet?text=${text}`, '_blank');
        }

        function shareOnLinkedIn() {
            const url = window.location.href;
            window.open(`https://www.linkedin.com/sharing/share-offsite/?url=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnFacebook() {
            const url = window.location.href;
            window.open(`https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnWhatsApp() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://wa.me/?text=${text}`, '_blank');
        }

        function shareViaEmail() {
            const url = window.location.href;
            window.location.href = `mailto:?subject=${encodeURIComponent(pageTitle)}&body=${encodeURIComponent('Check this out: ' + url)}`;
        }

        window.addEventListener('scroll', () => {
            const backToTop = document.querySelector('.back-to-top');
            if (window.scrollY > 300) {
                backToTop.classList.add('visible');
            } else {
                backToTop.classList.remove('visible');
            }
        });

        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({ behavior: 'smooth' });
                }
            });
        });

        // Feedback widget
        document.getElementById('feedbackPageUrl').value = window.location.href;
        function toggleFeedback() {
            document.getElementById('feedbackPanel').classList.toggle('open');
        }
        window.toggleFeedback = toggleFeedback;

        function submitFeedback(e) {
            e.preventDefault();
            const form = document.getElementById('feedbackForm');
            const type = form.querySelector('input[name="type"]:checked');
            const msg = document.getElementById('feedbackMsg').value;
            const email = document.getElementById('feedbackEmail').value;
            const pageUrl = window.location.href;
            const subject = encodeURIComponent('[AI 2030 Report] ' + (type ? type.value : 'Feedback') + ': ' + document.title.split(' - ')[0]);
            const body = encodeURIComponent(
                'Type: ' + (type ? type.value : 'N/A') + '\n' +
                'Page: ' + pageUrl + '\n' +
                'From: ' + (email || 'Anonymous') + '\n\n' +
                'Message:\n' + msg
            );
            window.location.href = 'mailto:narenbizymoms@gmail.com?subject=' + subject + '&body=' + body;
            form.style.display = 'none';
            document.getElementById('feedbackSuccess').style.display = 'block';
            setTimeout(() => {
                document.getElementById('feedbackPanel').classList.remove('open');
                setTimeout(() => {
                    form.style.display = '';
                    form.reset();
                    document.getElementById('feedbackSuccess').style.display = 'none';
                }, 300);
            }, 2000);
        }
        window.submitFeedback = submitFeedback;
    </script>
</body>
</html>
